Vega Therapeutics Acquired by Incyte | Healthcare M&A Deal

Incyte has completed the acquisition of Vega Therapeutics, a pharmaceuticals business in the U.S., for $1.25 billion. Incyte acquisitions add Vega Therapeutics’ late-stage bleeding disorder pipeline, including VGA039, a monoclonal antibody being studied in phase 3 for von Willebrand disease (VWD). Vega Therapeutics focuses on protein modulation to support hemostasis, aiming to expand treatment options beyond Takeda’s Vonvendi for on-demand and prophylactic care. The strategic acquisition is structured as an add on acquisition, with up to $750 million in sales milestones, and is positioned to support Incyte growth as Jakafi faces patent expiration risk in 2028.